Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2GJ4P
|
|||
| Drug Name |
TP-1287
|
|||
| Synonyms |
UNII-7MPP85IIJ3; 7MPP85IIJ3; CHEMBL4594423; SCHEMBL18251861; 2044686-42-0; 4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5-hydroxy-8-((3S,4R)-3-hydroxy-1-methyl-4-piperidinyl)-7-(phosphonooxy)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Sumitomo Dainippon Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21ClNO8P
|
|||
| Canonical SMILES |
CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)OP(=O)(O)O
|
|||
| InChI |
1S/C21H21ClNO8P/c1-23-7-6-12(16(26)10-23)19-18(31-32(27,28)29)9-15(25)20-14(24)8-17(30-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,16,25-26H,6-7,10H2,1H3,(H2,27,28,29)/t12-,16+/m0/s1
|
|||
| InChIKey |
YRNFLVUMZIRYKY-BLLLJJGKSA-N
|
|||
| CAS Number |
CAS 2044686-42-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclin-dependent kinase 9 (CDK9) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Reactome | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
| WikiPathways | Cardiac Hypertrophic Response | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Host Interactions of HIV factors | ||||
| HIV Life Cycle | ||||
| IL-9 Signaling Pathway | ||||
| RNA Polymerase II Transcription | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03604783) Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.